Get in Touch
We love to help & we love to listen. Please fill out the form
below and we’ll get back to you within a day
Inuvo, Inc. (NYSE:INUV) announced its financial results for the first quarter ended March 31, 2025, on Friday.
Revenue climbed 57% year-over-year to $26.7 million, marking the highest revenue in the company’s history. The analyst consensus estimate was $23.7 million.
A 61% increase within Platforms and a 31% increase within Agencies & Brands drove the topline growth.
Also Read: Inuvo Is Better Aligned With Consumer Demand For Privacy, New Regulations: Analyst
The revenue cost was $5.6 million, compared to $2.1 million Y/Y, due to higher Platform revenue and introducing a new product.
Gross profit increased 41% to $21.1 million. Due to changes in product mix, the margin declined to 79%, down from 87.7% year over year.
Net loss per share was 1 cent, in line with the analyst consensus estimate and compared to a loss of 2 cents a year ago.
The adjusted EBITDA loss was $22 thousand, compared to a $1.0 million Y/Y loss. Inuvo held $2.6 million in cash and equivalents as of March 31, 2025.
During the quarter, the company launched the enhanced IntentKey Self-Serve Platform, an advanced AI agent for audience discovery and targeting.
It added 20 new IntentKey clients and now has 15 self-service clients.
CEO Richard Howe said it marked its second consecutive quarter, with 57% Y/Y growth driven by both product lines, despite the first quarter being its typically weakest quarter.
Price Action: At the last check on Friday, INUV stock traded higher by 3.81% to $0.409 premarket.
Read Next:
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) on Thursday announced that the FDA has granted the company's request for an End of Phase 2 meeting to discuss its proposed clinical development plan and seek the U.S. Food and Drug Administration (FDA) guidance on the Phase 3 clinical trial for AD04.
The meeting will take place on July 25, 2025. AD04 is the company's lead investigational genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients (defined as < 8 drinks/day).
Cary Claiborne, President and Chief Executive Officer of Adial, commented, "We recently announced the successful results of our Type D Meeting with FDA, confirming Adial's 505(b)(2) regulatory bridging strategy. Concurrently, we have made strong progress in developing the design of our Phase 3 trial and look forward to aligning with the FDA on key requirements to move AD04 forward. Our recent analyses have reinforced the selection of our target patient population and continue to support AD04's potential to effectively treat AUD and related conditions. We remain confident in the path ahead and look forward to sharing a comprehensive update following our FDA meeting in July."
In February, Adial Pharmaceuticals announced a positive response from the FDA regarding its proposed in vitro bridging strategy for AD04.
The FDA's feedback follows Adial's submission in November 2024, in which the company sought the agency's guidance on aligning its AD04 formulation strategy and bridging approach.
With this regulatory confirmation, Adial is manufacturing clinical supply materials in preparation for its upcoming Phase 3 program in 2025.
Adial Pharmaceuticals announced that patent number 12,221,654 was issued by the United States Patent and Trademark Office on February 11, 2025.
The patent expands the covered methods of identifying patients with specific genetic markers linked to substance use disorders and treating them with AD04, the company's investigational new drug product.
Price Action: ADIL stock traded lower by 3.31% to $0.63 premarket at the last check on Thursday.
Read Next:
Mira Pharmaceuticals, Inc.’s (NASDAQ:MIRA) Board of Directors unanimously approved on Thursday the planned acquisition of SKNY Pharmaceuticals, Inc., following the completion of independent valuation reports on both companies.
In March, MIRA Pharmaceuticals signed a binding letter of intent (LOI) to acquire SKNY Pharmaceuticals. Under the terms, MIRA will acquire SKNY through a stock exchange, whereby SKNY shareholders will receive shares of MIRA common stock at a valuation determined by an independent third-party firm.
A third-party analysis conducted by Moore Financial Consulting assigned SKNY Pharmaceuticals an enterprise value of approximately $30.5 million, based on a risk-adjusted net present value (rNPV) of its lead compound, SKNY-1.
Mira was separately valued at $30 million, further validating the strength and synergy of the combined pipeline.
As outlined in the binding letter of intent, the transaction includes a $5 million contribution from SKNY to Mira in cash or other assets, to be transferred at closing.
The company is preparing a filing with the U.S. Securities and Exchange Commission to seek shareholder approval.
As Mira advances this merger, the combined enterprise value of over $60 million, grounded in third-party analysis, represents a strong platform for expansion into high-value therapeutic markets.
Mira CEO Erez Aminov said the acquisition “brings together two pipelines, two market opportunities, and one unified strategy: developing targeted, first-in-class therapies for urgent public health needs.”
SKNY-1 is being developed as a next-generation oral therapeutic designed to modulate CB1 and CB2 cannabinoid receptors, as well as monoamine oxidase B (MAO-B)—an enzyme involved in dopamine metabolism and addiction regulation.
On Tuesday, MIRA Pharmaceuticals released results from a neurotoxicity study of Ketamir-2, its novel oral NMDA receptor antagonist.
Price Action: At the last check Thursday, MIRA stock was down 2.59% at $1.12 during the premarket session.
Read Next:
On Thursday, Aduro Clean Technologies Inc. (NASDAQ:ADUR) announced the signing of a Memorandum of Understanding (MOU) with Cleanfarms Inc., a prominent Canadian organization specializing in agricultural waste management.
This strategic, multi-phase collaboration will explore the technical and commercial feasibility of Aduro's proprietary Hydrochemolytic Technology (HCT) as a scalable solution for chemically recycling on-farm plastics that are difficult to process through conventional methods.
By combining Aduro's advanced recycling technology with Cleanfarms' leadership in agricultural plastic stewardship, the initiative aims to convert materials unsuitable for mechanical recycling into valuable feedstock—potentially enabling a circular economy in the agri-plastics sector.
"Our goal is to develop a commercial pathway for difficult-to-recycle agriculture waste, waste streams that are strong candidates for Aduro's HCT and are currently overlooked by conventional technologies," said Ofer Vicus, Chief Executive Officer at Aduro.
"Cleanfarms brings deep knowledge of the agricultural waste landscape and a national supply chain that can support our evaluation of HCT on real-world farm plastic materials. Together, we're building the foundation for a solution to reduce landfilling and open new value streams," added Vicus.
The collaboration will follow a three-phase, stage-gated approach to assess the technical and economic feasibility of using Aduro's Hydrochemolytic™ Technology to recycle post-consumer agricultural plastics.
Price Action: On the last check Thursday, ADUR shares were trading higher by 0.72% at $5.57 premarket.
Photo by Boy Anthony via Shutterstock
For years, people made the same joke: "Does ‘Edible Arrangements’ sell edibles?"
Now, it does.
Edible Brands—the parent company behind the fruit bouquet giant with more than 800 locations and roughly $500 million in annual revenue—has officially entered the cannabis-adjacent space. But instead of leaning into novelty, the company is positioning itself as a responsible operator in a murky and fast-growing category: hemp-derived THC.
Its new venture, Edibles.com, launched earlier this year as a curated e-commerce marketplace offering low-dose THC products from brands like Cann, Wana, 1906 and Happi. While the site's branding is light on references to Edible Arrangements, the infrastructure and ambition behind it reflect the scale of a company that has delivered fruit bouquets to millions.
"We've had this idea for a long time," said CEO Somia Farid Silber in an exclusive interview with Benzinga Cannabis. "It was kind of this casual, running joke—‘Do you sell edibles?'—but once we owned the domain, we realized we had an opportunity to build something trusted. Something that helps people live better, not just get high."
When Thomas Winstanley, former chief marketing officer at craft cannabis company Theory Wellness, first heard about the project, he didn't quite get it.
Photo: Thomas Winstanley
"I was skeptical at first," he admitted. "It was like—wait, you have edibles.com? You want to come into this space? Why?"
Winstanley, who'd helped build one of the East Coast's most recognized cannabis brands, had seen how messy the industry could be. He didn't want to be the "weed guy they brought in" just to slap THC labels on fruit baskets.
Also read: The Broccoli Hack: How Mexican Creators Bypassed TikTok’s Rules To Teach Millions About Cannabis
But as he dug deeper, he saw something rare: infrastructure. Edible Brands had a high-performing e-commerce system that processed roughly $300 million in annual sales, a nationwide last-mile delivery network and leadership that was genuinely interested in doing it right.
"I didn't want to come in like a bull in a china shop and just try to peddle a bunch of products," he said. "What drew me in was the opportunity to build something with integrity, something rooted in wellness."
Photo: Somia Farid Silber
Farid Silber had already positioned Edibles.com as a standalone platform—separate from Edible Arrangements, but powered by the same operational backbone.
"We're building out a platform that's all about gifting, food, health and wellness," she said. "This is the wellness part."
Edibles.com doesn't sell THC-laced strawberries or cannabis-infused gift towers. And that's the point.
Instead of mimicking Edible Arrangements' gifting model, the site launched as a curated online marketplace with clean design, a limited product selection and no gimmicks. It features gummies, drinks and lozenges from trusted third-party hemp brands. No house products—for now. No novelty packaging.
"We might do something like that in the future," said Farid Silber, referring to the idea of THC-infused gifts. "But today, it's really about creating a space where we can highlight all these amazing brands—and using our last-mile delivery advantage to get products to consumers quickly and affordably."
The absence of gifting isn't philosophical; it's logistical. While hemp-derived THC is federally legal under the 2018 Farm Bill, state rules vary widely. In Georgia, for example, consumers can find high-dose Delta-9 products at gas stations. But shipping a curated THC gift box across multiple states? That's much trickier.
"For now, we're focused on personal use and building trust," Farid Silber said.
Winstanley put it more bluntly: "I don't want to send my mom a gift box of THC chews that she thinks are candy, especially when she has no idea what's in them, how strong they are or how much to take."
While the name might suggest a party crowd, Edibles.com leans heavily into functionality and wellness, positioning THC as an alternative to alcohol or a tool for better sleep and stress management.
"When you're introducing a product category with this much baggage and confusion, you have to meet consumers where they are," Winstanley said. "This is about offering a safer, more straightforward way for people to try or access THC."
Farid Silber, who's new to the cannabis industry, said her own learning curve helped shape the platform's focus on education.
Also read: ‘Willy Wonka Of Weed’ Opens The Doors To The RAW Factory: Here’s What We Saw
"There's just so much out there," she said. "What's the difference between CBD and CBN? What's right for sleep? For energy? We want Edibles.com to be a destination where people can learn and shop safely without feeling overwhelmed or judged."
Over time, the company hopes to build a broader content hub covering cannabis, nutraceuticals and wellness tools. For now, the focus is simple: low-dose THC, clear information and a judgment-free experience.
For consumers in states without dispensaries, the THC experience often starts in less-than-ideal places.
"I was totally blown away," Winstanley said. "Seeing a thousand-milligram chew in a gas station was scary. Coming from regulated cannabis, it felt really foreign—and really dangerous."
Even internally, the lack of awareness was jarring.
"One executive told me, ‘Oh, I just went to a dispensary and got these products,'" Winstanley recalled. "And I had to say—no, you didn't. There are no dispensaries here."
That, he said, underscores the brand's larger mission: to help people distinguish between vetted products and random street-level stuff.
"We want to be a trusted marketplace," he said. "For that, you have to curate."
The company's first phase launched in Texas, followed by Georgia, the Carolinas and Florida. All were chosen for a reason: they represent large populations underserved by cannabis infrastructure.
"Last mile in Texas was phase one," Winstanley said. "Now that we know the engine runs, it's time to scale."
Nationwide shipping is next. And in Atlanta, Edibles.com is opening its first flagship retail store, designed to mirror the e-commerce experience but offer in-person support.
"It gives people a place to talk to someone and walk out with something in hand," he said. "In a state without dispensaries, that's a big deal."
A franchise model is on the table, potentially offering a "dispensary-lite" opportunity for operators who want to sell low-dose THC without the cost or red tape of traditional licensing.
Winstanley tracks hemp regulations "almost daily," especially in states like Texas and Florida. But he doesn't view oversight as a threat. In fact, he welcomes it.
"I would never have said this back when I was in cannabis," he told Benzinga, "but regulation in this category can be a net positive. It helps weed out bad actors. It legitimizes good ones. And it creates a safer space for the consumer."
He cited Texas's SB3 bill, which originally aimed to ban hemp-derived THC, as a turning point. The bill stalled after an 18-hour hearing where residents spoke passionately in defense of the category.
"There's growing awareness that policy needs to catch up to reality," he said. "Legalization happened. Now we need to frame it responsibly."
That includes pushing for milligram caps, licensing models and clear enforcement that preserves access while protecting consumers.
With its infrastructure and reach, it's only a matter of time before Edibles.com launches its own branded line.
"We know what we want to make," Winstanley said. "But we're not rushing. This isn't about putting our name on something and flooding the site. It's about finding the right partners, the right formulations and the right voice."
He previously managed more than 250 SKUs at Theory Wellness and helped launch one of the first automated cannabis canning lines on the East Coast. Still, this time, the team is taking it slow.
"We could go out and slap a label on a bag of chews tomorrow," he said. "But that's not the kind of company we are. We want to do it right—and that means learning first, then launching."
Edibles.com may have launched with a wink and a clever domain name, but the team behind it isn't playing for laughs.
"This is something serious," Farid Silber said. "We know the name gets attention, but we didn't build this to go viral or be cute. We built it to help people live better. And that only works if you build it right."
So far, the gamble seems to be paying off. The company hasn't shared early sales figures, but reports an "overwhelmingly positive" response. With expansion underway, a flagship store in development and a potential franchise model on the horizon, Edibles.com is positioning itself for real staying power.
It may not look like cannabis retail as we know it, but that's kind of the point.
Photos courtesy of Edible Brands
President Donald Trump recently passed the 100-day milestone for his second presidential term after winning the 2024 election.
A new Benzinga reader poll shows Trump’s approval rating for his first 100 days in the White House and how that compares to a survey from his first 52 days.
What Happened: Presidents are often scored on their first 100 days in office as a milestone figure used to show what has been accomplished in terms of campaign promises, laws passed and voters’ feelings about the candidate after they officially take office.
A new Benzinga reader poll shows Trump's approval rating after his first 100 days in the White House.
“How do you feel about Donald Trump’s first 100 days back in office?” Benzinga asked.
The results were:
After stripping out the 46% of voters who did not vote for Trump, the president’s approval rating from people who voted for him in the poll looks like this:
The poll shows a strong favorable rating for Trump, but it comes with the caveat that this is voters who selected him in the 2024 presidential election.
Trump's favorable rating is also down from a Benzinga survey that asked the same question after 52 days back in March. In the previous poll, 37% said they approved Trump's first 52 days, while 15% disapproved. Forty-four percent said they didn't vote for Trump, and 4% said they voted for Trump and had no strong opinion.
In that previous poll, Trump had a favorable rating of 69.4% and an unfavorable rating of 28.6% when the respondents who did not vote for him were removed.
This means that Trump's approval rating has gone down, while his unfavorable rating also went down with more voters undecided on their approval level of the current president.
If the 46% of the poll who said they didn't vote for Trump were included, the approval rating would likely be significantly lower. The 63.1% favorable rating is based only on the Benzinga readers who answered the poll and voted for Trump in the 2024 election.
Why It's Important: Other 100-day polls show low approval ratings for Trump. An Emerson College poll shows a 45% approval rating and a 45% disapproval rating. The remaining 10% are neutral on the current president.
This approval rating is down two percentage points from Trump's first 50 days, while the disapproval rating stayed the same.
One item likely weighing on the minds of Benzinga readers in the poll is the performance of the S&P 500 during Trump's first 100 days in office.
The SPDR S&P 500 ETF Trust (NYSE:SPY) tracks the S&P 500. It was down 7.8% from the closing price on Jan. 17, before Trump's inauguration, to the closing price on Trump's 100th day.
According to CNBC, the drop in the S&P 500 was the worst start to a four-year term since Richard Nixon in 1973, citing data from CFRA Research.
In 1973, the S&P 500 fell 9.9% in the first 100 days of Nixon's presidency. For comparison, the S&P 500 has an average return of 2.1% in the first 100 days of a presidency, dating back to 1944.
Also, keep in mind that recent presidents had some of the best stock market performances in their first 100 days in office. Here are the recent returns and their rating since 1944:
Markets traded higher in November and December after Trump’s win, with some of the largest companies in the world hitting new all-time highs. January and February also saw gains after Trump took office.
In March and April, attention shifted towards economic and foreign policies, with markets diving in April after Trump’s tariff announcement.
While voters have different reasons why they voted for a candidate and different criteria they score a favorable or approval rating on, Benzinga readers could be knocking Trump's rating down due to the poor stock market performance during his first 100 days.
The stock market saw strong returns during Trump's last presidential term, which included his first year in office and the four-year term.
Trump’s first 100 days represent a portion of the 1,461 days the president would have under his current term, or roughly 6.8%.
Did You Know?
The study was conducted by Benzinga from April 30, 2025, through May 2, 2025. It included the responses of a diverse population of adults 18 or older. Opting into the survey was completely voluntary, with no incentives offered to potential respondents. The study reflects results from 225 adults.
Photo: Shutterstock
Alzamend Neuro, Inc. (NASDAQ:ALZN) on Wednesday announced its partnership with Mint Labs Inc. d/b/a QMENTA, a medical imaging artificial intelligence company, to support its five upcoming Phase 2 trials of AL001 at Massachusetts General Hospital.
QMENTA's cloud-based platform will manage and analyze medical imaging data throughout the trials, ensuring regulatory compliance, enhancing operational efficiency and supporting data management.
Also Read: EXCLUSIVE: Alzamend Neuro To Start First Phase 2 Study For Lead Candidate In 2025
In collaboration with QMENTA and Massachusetts General Hospital as its clinical trial site, Alzamend aims to explore the properties of AL001 and its potential to deliver lithium more effectively in the brain compared to marketed lithium salts.
The study in healthy human subjects will serve as a baseline and assist Alzamend to determine the best path forward in Alzheimer's, bipolar disorder, major depressive disorder, and post-traumatic stress disorder patients by demonstrating AL001's targeted effectiveness and reduced systemic side effects.
Previous studies in mice have shown that AL001 ensures better brain absorption while maintaining lower levels of lithium in the blood, paving the way for safer and more efficient treatments.
In March, Alzamend Neuro announced its plans to initiate a phase 2 clinical study of AL001 for patients with post-traumatic stress disorder in the fourth quarter of 2025.
In March, Alzamend Neuro announced its plans to initiate a phase 2 clinical study of AL001 for bipolar disorder, which is expected to commence in the third quarter of 2025.
Price Action: At the last check on Wednesday, ALZN stock was up 0.09% at $0.64 during the premarket session.
Read Next:
If you were to ask a veteran investor if there’s a 100% international equity ETF that’s up more than 16% year-to-date in 2025, they’d likely answer with a healthy dose of skepticism and a side of disbelief.
In an exclusive sit-down with Bancreek Capital CEO Andrew Skatoff, one thing became clear: the idea that international equity ETFs are boring, over-diversified and underperforming is in line for a do-over. Skatoff’s fund, the Bancreek International Large Cap ETF (NYSE:BCIL), has flipped that narrative. With a number 1 rank out of 1,053 active and passive ETFs in April, according to Bloomberg, BCIL is demonstrating that a concentrated international portfolio can beat bloated benchmarks and old-school incumbents.
This ETF’s approach is simple yet successful: target international firms with what Bancreek defines as “institutional endurance”— companies with durability, resilience, longevity and growth. It isn’t buzzword stew, it’s model-based, high-conviction strategy that winnows thousands of developed-market stocks down to the ones that count.
“At any given time, there may only be 50 such businesses in our investable universe,” Bancreek Capital Advisors CEO Andrew Skatoff says. “Through extensive research, we've found that 30 positions strike the right balance between long-
term compounding potential and near-term volatility management. Holding significantly more positions in the portfolio dilutes this quality and erodes risk-adjusted returns. That's our edge — precision over breadth.”
The ETF’s portfolio is surprisingly evenly weighted. Concentrated, yes, but closer to equal-weight than most passive funds. BCIL’s top 10 holdings, for example, account for just about 40% of the fund — scarcely more concentrated than the S&P 500, which has 16x as many names but a 36% top-10 weight.
Let's face it: for the past decade, international equities have had little appeal — mildly interesting but quickly discarded. But the tide may be turning.
"The global trade landscape is shifting. U.S. policy decisions are increasingly disrupting long-standing trade flows. If the U.S. turns inward, those opportunities will likely be backfilled by regional champions in countries like Japan, the U.K., Canada, and Australia," Skatoff notes. Add in the valuation gap between U.S. and international markets, and you've got a real opportunity for alpha generation.
International developed markets are still discounted to the U.S., even with recent good performance. And with themes such as supply chain regionalization and geopolitical rebalancing gaining traction, BCIL’s timing begins to feel more like a strike and less like a contrarian bet.
At the center of Bancreek’s strategy is a proprietary quantitative engine — one that’s been refined by years of basic research but engineered for speed and scale.
“These models were built on years of deep fundamental research and have gone through countless iterations to find the right set of variables to help us identify these structurally advantaged businesses,” Skatoff says. “Now, our models can do it systematically, with speed and consistency — and we can deliver that efficiency to retail investors through our ETFs.”
The model focuses on not only the financial health but also the quality of capital deployment, business model robustness, and scalability — metrics that generally translate well internationally.
Critics balk at the 30 stocks in this global fund. But BCIL isn’t quantity, it’s quality with built-in diversification. One of the holdings, for instance, is a software aggregator that owns over 500 companies — a fund within a fund, of sorts.
“We believe in outsourcing diversification to the companies themselves — specifically, to world-class management teams with a proven ability to identify and acquire high-quality businesses,” Skatoff says.
With only 30 names, BCIL has shown less volatility than the FTSE Developed ex-US All Cap Index, which contains over 3,000 stocks, noted Skatoff. Evidence that when it comes to building a portfolio, less can be more — if you choose wisely.
Although BCIL targets established international names, Bancreek also manages a U.S. large-cap strategy, the Bancreek U.S. Large Cap ETF (NYSE:BCUS), based on the same system.
“Both ETFs use the same investment engine — the difference lies in the universe: BCUS draws from U.S. large caps, while BCIL focuses exclusively on developed international names,” said Skatoff.
Though overshadowed by BCIL’s star turn, BCUS has also beaten the S&P 500 in 2025 and navigated volatility with aplomb, especially in a volatile month like April. Together, they form Bancreek’s two-engine style of equity investing: same strategy, alternate hunting grounds.
And for now, the results speak louder than any marketing brochure ever could.
Read Next:
Photo: Gumbariya via Shutterstock
Gold’s latest surge, inspired by China’s safe-haven dash, a declining dollar and a geopolitical situation more knotted than a string of Christmas lights—has investors abuzz. While spot gold jumped 3.03% on Tuesday to $3,414.24, astute gold seekers are digging deeper.
Meet the VanEck Merk Gold ETF (NYSE:OUNZ), the golden child of physically backed ETFs that offer a “just-in-case” delivery feature for those who prefer their portfolios to include physical bullion.
Merk Investments president and CIO Axel Merk told Benzinga that this golden opportunity is not coincidental. “In the current environment, tariffs may well alter the plumbing of the global financial system,” he said, citing increasing anxiety about monetary policy, recession fears and the potential for U.S.–China tariff disruption to divert global financial plumbing. “Add to this a highly leveraged financial system, and we see a growing number of investors turning to gold in anticipation of a range of potential unintended consequences, including pressure on the Federal Reserve to lower interest rates.”
An ETF Containing Actual Gold
What distinguishes OUNZ isn’t merely its paltry 0.25% expense ratio (comparable to iShares Gold Trust (ARCA: IAU), lower than SPDR Gold Trust (NYSE:GLD)), but its special benefit: investors can receive physical gold—whether London Bars or Maple Leafs. Merk’s patented conversion process enables these large bullion bars to be converted into investor-friendly coins, making OUNZ the ETF version of an alchemist with excellent logistics.
Year to date, the fund has experienced more than $150 million in inflows, according to Merk, marching in tandem with gold’s rising surge. While not all exchange their ETF shares for glittering coins, six deliveries have already been made this year, primarily by high-net-worth individuals seeking something more tactile than spreadsheets.
Long-Term Mindset In A Short-Term World
OUNZ is not your typical trader’s sandbox. Most investors go in on its delivery option rather than the action. “Many investors are drawn to OUNZ because of the option to take physical delivery, even if they never exercise it. As a result, OUNZ tends to attract long-term holders rather than short-term traders. This was evident last year when other gold products saw outflows while OUNZ maintained steady inflows. We typically process a few deliveries each month; year-to-date, there have been six,” Merk said, crediting the ETF’s popularity with long-term holders who enjoy converting financial worry into something they can pile in a safe.
Tax-Smart And Apocalypse-Ready?
Receiving delivery of gold via OUNZ is not taxable since you’re technically not claiming anything you don’t already possess. It’s the gold version of grabbing a pizza you’ve already paid for online. Just don’t go for a Krugerrand, though. Its below-95% purity makes it a tax gray area, warns Merk.
Greater Appeal In An Unpredictable World
In the post-pandemic era, investor demand for physical gold has widened. The erstwhile niche “gold bug” segment has mainstreamed, with inflation anxiety and sovereign debt mountains rising. Merk assertively believes this is just the start. And while central banks continue to pile up gold, OUNZ’s inflows are less a product of panic buying and more a function of careful strategy.
However, sound retail interest is driving the success of the ETF. “While demand for OUNZ has increased, we have not seen signs of panic buying. Importantly, coin premiums have not spiked—typically a telltale sign of strong retail engagement. While retail interest has grown, much of the buying has come from institutions. In that sense, central bank gold purchases have not directly influenced retail appetite,” Merk explained.
The Bottom Line
As macro uncertainty simmers, Fed announcements loom and Trump hints at trade agreements, the OUNZ provides more than gold exposure. It provides flexibility, tranquility, and sure, real gold in your pocket if the mood (or market) strikes.
Read Next:
Photo: Shutterstock
DeFi Development Corp (NASDAQ:DFDV), formerly Janover Inc., announced on Tuesday that it had purchased approximately 82,404.50 Solana (CRYPTO: SOL) tokens.
Following this transaction, DeFi Development now holds approximately 400,091 SOL, valued at $58.5 million, including staking rewards.
As of May 06, 2025, DeFi Development held 400,091 SOL worth $58.5 million.
Its total shares outstanding was 2,001,887, SOL per share was $29.24
A portion of the Solana acquired includes locked SOL sourced via BitGo's OTC desk, facilitating purchases from institutional sellers subject to time-based unlock schedules.
Price Action: DFDV stock closed at $71.89 on Monday.
Read Next:
Photo via Shutterstock
Quick Contact
Address
1 Campus Martius Detroit,
MI 48226, United States
Phone
Get in Touch
We love to help & we love to listen. Please fill out the form
below and we’ll get back to you within a day
Customer Support
© 2023 Benzinga APIs | All Rights Reserved
